TrialJournal of the European Academy of Dermatology and Venereology : JEADV2020

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis.

J F Merola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.